drugset / Trial / NCT03042741
Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity
Phase 3
Unknown
300 enrolled
Immunitor LLC
Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Atherosclerosis vaccine, V6, has been through two small-scale Phase II open label clinical trials. It has shown significant improvement in lipid profile in patients with overweight or obesity
Timeline
- Start
- 2017-02-01
- Primary completion
- 2019-12-18
- Completion
- 2019-12-18
Publications
- Background Bourinbaiar AS, Jirathitikal V. Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices. Vaccine. 2010 Mar 24;28(15):2763-8. doi: 10.1016/j.vaccine.2010.01.032. Epub 2010 Jan 29.
- Background Bourinbaiar AS, Jirathitikal V. Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study. Lipids Health Dis. 2010 Feb 2;9:14. doi: 10.1186/1476-511X-9-14.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | atherosclerosis vaccine | Vaccine | — | Oral |